【摘要】 目的探讨厄洛替尼治疗晚期非小细胞肺癌临床疗效的影响因素。方法将208例晚期非小细胞肺癌按照中位无进展生存期分为两组,中位无进展生存期≥5个月者设为A组(101例),中位无进展生存期<5个月者设为B组(105例)。两组均给予厄洛替尼联合贝伐单抗治疗,观察直至疾病进展或者死亡。比较两组患者的一般资料,分析两组临床疗效影响因素。结果两组患者性别、年龄、吸烟史、病理分型、疾病分期比较差异有统计学意义(P<0.01),A组患者男性比例、年龄、吸烟史比例显著<B组(P <0.01),腺癌及Ⅲ期患者比例显著>B组(P<0.01)。吸烟史及病理分型是厄洛替尼治疗晚期非小细胞肺癌患者临床疗效的影响因素(P<0.05)。结论吸烟史及病理分型是厄洛替尼治疗晚期非小细胞肺癌患者临床疗效的影响因素,无吸烟史及腺癌患者无进展生存期更久。更多还原

【Abstract】 Objective To investigate the influencing factors of clinical efficacy of erlotinib in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 208 patients with advanced NSCLC were divided into two groups according to the middle progress free survival(MPFS).Patients with MPFS≥ 5 months were set as group A(101 cases),and those with MPFS less than 5 months were set as group B(105 cases).Both groups were treated with erlotinib combined with bevacizumab and observed until disease progression or death.The general data of the two groups of patients were compared,and the factors affecting the clinical efficacy of the two groups were analyzed.Results There were statistically significant differences between the two groups of patients in gender,age,smoking history,pathological type,and disease stage(P<0.01).The proportion of males,age and smoking history in group A were significantly lower than those in group B(P<0.01),and the proportion of adenocarcinoma and stage III patients was significantly higher than that in group B(P<0.01).Smoking history and pathological type were the influencing factors of the clinical efficacy of erlotinib in the treatment of patients with advanced NSCLC(P<0.05).Conclusions Smoking history and pathological classification are factors influencing the clinical efficacy of erlotinib in patients with advanced NSCLC.Patients without smoking history and adenocarcinoma patients have longer PFS.更多还原